Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Pharmacy Enterprise, South Eastern Norway | OTHER |
Not provided
Not provided
Not provided
Not provided
Medication errors represent the most common cause of patient injury and one of the most frequently reported health related deviation in Norway. The addition of a dedicated clinical pharmacist throughout the hip fracture patient pathway (patient pathway pharmacist) is believed to improve patient safety and ensure optimal drug-related patient care. The pharmacist will perform medication reconciliation at admission to hospital, medication review after surgery and assist physicians with discharge summary. Six weeks after discharge the patient pathway pharmacist will perform a second drug reconciliation and medication review. This study will assess the pharmacists' place and specific tasks in the patient pathway, describe areas where the pharmacist contribute to increased quality of care and assess the benefits and/or disadvantages experienced with introducing a patient pathway pharmacist. The estimated number of patients included is 60. Current practice will be determined by investigating the last 50 patients' medical record and a questionnaire to health care professionals involved in treatment of hip fracture patients. Data from medication reconciliation and drug review will be collected and compared to current practice. After the inclusion period, focus group surveys and/or semi-structured interviews will be executed to describe the perceived improvement in the quality of care. Primary endpoints are: 1) Medication reconciliation score at admission 2) Number of inappropriate drugs for elderly 3) Discharge summary score 4) Discharge summaries following procedure. Secondary endpoints are readmissions and mortality after 30 and 90 days. Qualitative endpoints: 1) Health care professionals experience of current drug-related practice 2) Experienced advantages and disadvantages of a patient pathway pharmacist.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient Pathway Pharmacist intervention | Experimental |
|
|
| No intervention | No Intervention | Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient Pathway Pharmacist intervention | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| Discharge summary score | In the discharge summary, the section describing drugs is scored in accordance with the national patient safety program | At discharge (estimated five days after fracture/inclusion) |
| Admission summary score | In the admission summary, the section describing drugs is scored. The score is adjusted from the discharge summary score to fit the admission note. | At hospital admission (estimated to be within 24 hours after fracture) |
| Discharge summaries written in accordance with procedure | In the discharge summary, the section describing drugs should be in accordance with procedure. | At discharge (estimated five days after fracture/inclusion) |
| Number of inappropriate drugs at discharge | After surgery the medication review may reduce the number of inappropriate drugs (on the STOPP-list). | During hospitalisation, after surgery (estimated to be within five days after fracture/inclusion) |
| Measure | Description | Time Frame |
|---|---|---|
| Readmission | Patients who are readmitted to hospital is quantified | 30 days after discharge |
| Readmission | Patients who are readmitted to hospital is quantified |
| Measure | Description | Time Frame |
|---|---|---|
| Experience of current practice | A questionnaire will be distributed to all health care professionals involved in the treatment of hip fracture patients | Prior to or during the early start of the intervention |
| Experience of patient pathway pharmacist |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vestfold Hospital Trust | Tønsberg | Norway |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37312222 | Derived | Henriksen BT, Krogseth M, Andersen RD, Davies MN, Nguyen CT, Mathiesen L, Andersson Y. Clinical pharmacist intervention to improve medication safety for hip fracture patients through secondary and primary care settings: a nonrandomised controlled trial. J Orthop Surg Res. 2023 Jun 13;18(1):434. doi: 10.1186/s13018-023-03906-2. |
| Label | URL |
|---|---|
| Score of the drug section in discharge summaries - The Norwegian Patient Safety Programme: In Safe Hands | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006620 | Hip Fractures |
| D025981 | Hip Injuries |
| D050723 | Fractures, Bone |
| D005264 | Femoral Fractures |
| D005265 | Femoral Neck Fractures |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
| D007869 | Leg Injuries |
Not provided
Not provided
An intervention group is compared to a cross-sectional retrospective group.
A group of 60 patients with hip fracture will get an intervention by a clinical pharmacist who performs medication reconciliation and medication review during hospitalisation, they will receive a discharge summary where the medication part is optimised. After six weeks the patients will be get a follow-up with a second medication reconciliation and - review. This group will be compared with the last 50 patients with hip fracture who did not get the intervention.
Not provided
Not provided
Not provided
Not provided
|
| 90 days after discharge |
| Death | The number patients who dies is quantified | 30 days after discharge |
| Death | The number of patients who dies is quantified | 90 days after discharge |
Focus groups or semi-structured interviews will be performed to assess the advantages and/or disadvantages of introducing a patient pathway pharmacist.
| Within three months after last included patient |